Lodapolimab

洛达利单抗

Report date: 2022/07/04 19:38:02

Base Information

Drug NameLodapolimab
Drug Alias NameAnti-PD-L1 checkpoint antibody - Eli LillyLY-3300054
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsSkin MelanomaSolid tumoursMicrosatellite instability-high cancer +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsSkin MelanomaSolid tumoursMicrosatellite instability-high cancer +[5] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungTriple Negative Breast NeoplasmsCarcinoma, Renal Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A